Precise management of hepatopathy-related thrombocytopenia

Wanxin Shi; Huiwen Yan; Zhiyun Yang

doi:10.12449/JCH260902

Volume 42 Issue 9

Sep. 2026

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2026 > 42(9): 2006-2013

PDF( 1286 KB)

Precise management of hepatopathy-related thrombocytopenia

DOI: 10.12449/JCH260902

Wanxin Shi^{1, 2},
Huiwen Yan^{1, 2},
Zhiyun Yang^{1, 2
,
,
,}

1.
Center of Integrative Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China
2.
Laboratory for Clinical Medicine，Laboratory of Research and Translation of Traditional Chinese Medicine for Prevention and Treatment of Infectious Severe Liver Diseases，Capital Medical University，Beijing 100015，China

Research funding:

Beijing Research Ward Excellence Program (BRWEP2024W102170100);

Beijing Research Ward Excellence Program (BRWEP2024W102170116)

More Information

Corresponding author: Yang Zhiyun， yangzhiyun66@163.com （ORCID： 0000-0002-1522-0749）
Received Date: 2026-06-28
Accepted Date: 2026-09-13
Published Date: 2026-09-25

Abstract

Abstract

Hepatopathy-related thrombocytopenia （HRT） is a common complication in patients with chronic liver disease， and the development and progression of HRT involve multiple mechanisms including decreased platelet production， splenic sequestration， immune-mediated destruction， increased platelet consumption， and abnormalities in the bone marrow microenvironment. HRT not only increases the risk of bleeding but also hampers the successful implementation of antiviral therapy， antitumor treatment， and invasive procedures. In recent years， with the accumulation of evidence from basic and clinical studies， significant advances have been achieved in the pathogenesis， risk assessment， diagnostic stratification， and therapeutic strategies for HRT， and the paradigm of precise management has gradually shifted from merely increasing platelet counts toward a cause-directed， risk-stratified， and individualized intervention approach. With reference to the latest research advances in China and globally， this article reviews the new insights into the pathogenesis of HRT， refinements in diagnostic and risk assessment strategies， and the latest research advances in management strategies such as thrombopoietic agents， immunotherapy， invasive therapies， and integrated traditional Chinese and Western medicine therapies， in order to provide a reference for precise diagnosis， treatment， and clinical decision-making in HRT and to lay a foundation for establishing a future precise management system.
- Liver Diseases,
- Thrombocytopenia,
- Therapeutics

FullText(HTML)

References(65)

References

[1]	Gallo P, Terracciani F, di Pasquale G, et al. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures[J]. World J Gastroenterol, 2022, 28( 30): 4061- 4074. DOI: 10.3748/wjg.v28.i30.4061.
[2]	Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease[J]. Liver Int, 2017, 37( 6): 778- 793. DOI: 10.1111/liv.13317.
[3]	Lim H I, Cuker A. Thrombocytopenia and liver disease: Pathophysiology and periprocedural management[J]. Hematology Am Soc Hematol Educ Program, 2022, 2022( 1): 296- 302. DOI: 10.1182/hematology.2022000408.
[4]	Committee of Neoplastic Supportive-care(CONS), China Anti-Cancer Association. Chinese expert consensus on management of thrombocytopenia in cancer patients with liver injury(2022 edition)[J]. J Clin Hepatol, 2023, 39( 6): 1287- 1294. DOI: 10.3969/j.issn.1001-5256.2023.06.005. 中国抗癌协会肿瘤支持治疗专业委员会. 肿瘤合并肝损伤患者血小板减少症管理中国专家共识(2022版)[J]. 临床肝胆病杂志, 2023, 39( 6): 1287- 1294. DOI: 10.3969/j.issn.1001-5256.2023.06.005.
[5]	National Clinical Research Center for Infectious Diseases; Society of Hepatology, Beijing Medical Association; Translational Medicine Branch, Chinese Association of Gerontology and Geriatrics. Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia[J]. J Clin Hepatol, 2023, 39( 10): 2307- 2320. DOI: 10.3969/j.issn.1001-5256.2023.10.007. 国家感染性疾病临床医学研究中心, 北京医学会肝病学分会, 中国老年学和老年医学学会转化医学分会. 肝病相关血小板减少症临床管理中国专家共识[J]. 临床肝胆病杂志, 2023, 39( 10): 2307- 2320. DOI: 10.3969/j.issn.1001-5256.2023.10.007.
[6]	Karakas D, Xu M, Ni H Y. GPIbα is the driving force of hepatic thrombopoietin generation[J]. Res Pract Thromb Haemost, 2021, 5( 4): e12506. DOI: 10.1002/rth2.12506.
[7]	Rawi S, Wu G Y. Pathogenesis of thrombocytopenia in chronic HCV infection: A review[J]. J Clin Transl Hepatol, 2020, 8( 2): 184- 191. DOI: 10.14218/JCTH.2020.00007.
[8]	Lewis S A, Doratt B M, Qiao Q, et al. Integrated single cell analysis shows chronic alcohol drinking disrupts monocyte differentiation in the bone marrow[J]. Stem Cell Reports, 2023, 18( 9): 1884- 1897. DOI: 10.1016/j.stemcr.2023.08.001.
[9]	Rendina-Ruedy E, Rosen C J. Lipids in the bone marrow: An evolving perspective[J]. Cell Metab, 2020, 31( 2): 219- 231. DOI: 10.1016/j.cmet.2019.09.015.
[10]	Seufert A L, Hickman J W, Traxler S K, et al. Enriched dietary saturated fatty acids induce trained immunity via ceramide production that enhances severity of endotoxemia and clearance of infection[J]. eLife, 2022, 11: e76744. DOI: 10.7554/eLife.76744.
[11]	de Jonckheere B, Kollotzek F, Münzer P, et al. Critical shifts in lipid metabolism promote megakaryocyte differentiation and proplatelet formation[J]. Nat Cardiovasc Res, 2023, 2: 835- 852. DOI: 10.1038/s44161-023-00325-8.
[12]	Barrachina M N, Pernes G, Becker I C, et al. Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36[J]. Nat Cardiovasc Res, 2023, 2( 8): 746- 763. DOI: 10.1038/s44161-023-00305-y.
[13]	Fernández-Garibay V M, Ramírez-Mejia M M, Ponciano-Rodriguez G, et al. The mechanisms behind thrombocytopenia in patients with portal hypertension and chronic liver disease[J]. J Clin Transl Hepatol, 2025, 13( 11): 986- 991. DOI: 10.14218/JCTH.2025.00279.
[14]	Abdulrasak M, Someili A M, Mohrag M. Cytopenias in autoimmune liver diseases-a review[J]. J Clin Med, 2025, 14( 5): 1732. DOI: 10.3390/jcm14051732.
[15]	Christodoulou D, Katsanos K, Zervou E, et al. Platelet IgG antibodies are significantly increased in chronic liver disease[J]. Ann Gastroenterol, 2011, 24( 1): 47- 52.
[16]	Pereira J, Accatino L, Alfaro J, et al. Platelet autoantibodies in patients with chronic liver disease[J]. Am J Hematol, 1995, 50( 3): 173- 178. DOI: 10.1002/ajh.2830500305.
[17]	Zheng S S, Ahmadi Z, Leung H H L, et al. Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia[J]. Haematologica, 2022, 107( 9): 2195- 2205. DOI: 10.3324/haematol.2021.279751.
[18]	Xiao Han, Wang Li. Mechanisms of throm bocytopenia in liver cirrhosis[J]. J Pract Hepatol, 2019, 22( 4): 462- 465. DOI: 10.3969/j.issn.1672-5069.2019.04.003. 肖函, 王利. 肝硬化血小板减少的病理生理发生机制[J]. 实用肝脏病杂志, 2019, 22( 4): 462- 465. DOI: 10.3969/j.issn.1672-5069.2019.04.003.
[19]	Jiang Y Z, Tang Y Q, Hoover C, et al. Kupffer cell receptor CLEC4F is important for the destruction of desialylated platelets in mice[J]. Cell Death Differ, 2021, 28( 11): 3009- 3021. DOI: 10.1038/s41418-021-00797-w.
[20]	Deppermann C, Kratofil R M, Peiseler M, et al. Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets[J]. J Exp Med, 2020, 217( 4): e20190723. DOI: 10.1084/jem.20190723.
[21]	Su Y, Zhang T N, Qiao R. Pyroptosis in platelets: Thrombocytopenia and inflammation[J]. J Clin Lab Anal, 2023, 37( 4): e24852. DOI: 10.1002/jcla.24852.
[22]	Yang H X, Li Y J, He Y L, et al. Hydrogen sulfide promotes platelet autophagy via PDGFR-α/PI3K/Akt signaling in cirrhotic thrombocytopenia[J]. J Clin Transl Hepatol, 2024, 12( 7): 625- 633. DOI: 10.14218/JCTH.2024.00101.
[23]	El-Sayed N E T, Badr Eldin N M, Elrahman Sweilam M A, et al. The role of autophagy-related markers Beclin-1, LC3, and P62 in the pathogenesis of immune thrombocytopenia in children[J]. J Thromb Haemost, 2025, 23( 10): 3362- 3369. DOI: 10.1016/j.jtha.2025.06.034.
[24]	Zhuang W T, Zhang Y M. Research progress on the mechanism of ferroptosis and its application in primary immune thrombocytopenia[J]. J New Med, 2025, 56( 12): 1243- 1252. DOI: 10.12464/j.issn.0253-9802.2025-0302.
[25]	Luu S, Woolley I J, Andrews R K. Platelet phenotype and function in the absence of splenic sequestration(Review)[J]. Platelets, 2021, 32( 1): 47- 52. DOI: 10.1080/09537104.2020.1732322.
[26]	Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease[J]. J Thromb Haemost, 2021, 19( 4): 1116- 1122. DOI: 10.1111/jth.15239.
[27]	Liu S, Ma M, Qu J, et al. Arginine methylation by PRMT1 affects ADAMTS13 secretion and enzymatic activity[J]. Arterioscler Thromb Vasc Biol, 2025, 45( 4): 506- 522. DOI: 10.1161/atvbaha.124.322249.
[28]	Abdoul J, Luc N, Joly B S, et al. Total thrombus formation system exploration of primary hemostasis in cirrhotic patients[J]. Res Pract Thromb Haemost, 2026, 10( 1): 103370. DOI: 10.1016/j.rpth.2026.103370.
[29]	Efremova I, Maslennikov R, Poluektova E, et al. Gut microbiota and biomarkers of endothelial dysfunction in cirrhosis[J]. Int J Mol Sci, 2024, 25( 4): 1988. DOI: 10.3390/ijms25041988.
[30]	Violi F, Pastori D, Pignatelli P, et al. Endotoxemia and platelets: 2 players of intrahepatic microthrombosis in NAFLD[J]. JACC Basic Transl Sci, 2024, 9( 3): 404- 413. DOI: 10.1016/j.jacbts.2023.07.003.
[31]	Ono M, Toyomoto M, Yamauchi M, et al. Platelets accelerate lipid peroxidation and induce pathogenic neutrophil extracellular trap release[J]. Cell Chem Biol, 2024, 31( 12): 2085- 2095. e 4. DOI: 10.1016/j.chembiol.2024.11.003.
[32]	Wu X M, Jing H J, Jiang T, et al. Platelet-induced NET in liver cirrhosis: Mitochondrial ROS-mediated NETosis and its contribution to the hypercoagulable state[J]. Liver Int, 2025, 45( 8): e70223. DOI: 10.1111/liv.70223.
[33]	Wienkamp A K, Erpenbeck L, Rossaint J. Platelets in the NETworks interweaving inflammation and thrombosis[J]. Front Immunol, 2022, 13: 953129. DOI: 10.3389/fimmu.2022.953129.
[34]	Coz Yataco A, Soghier I, Hébert P C, et al. Transfusion of fresh frozen plasma and platelets in critically ill adults: An American college of chest physicians clinical practice guideline[J]. Chest, 2025, 168( 3): 661- 676. DOI: 10.1016/j.chest.2025.02.029.
[35]	Villa E, Bianchini M, Blasi A, et al. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis[J]. J Hepatol, 2022, 76( 5): 1151- 1184. DOI: 10.1016/j.jhep.2021.09.003.
[36]	Singh A D, Mucha S R, Lindenmeyer C C. Cirrhotic coagulopathy: A rebalanced hemostasis[J]. Cleve Clin J Med, 2022, 89( 9): 523- 533. DOI: 10.3949/ccjm.89a.21018.
[37]	Elvers F L, Lisman T. Rebalanced hemostasis, bleeding, and thrombosis in liver disease: A comprehensive review of pathophysiology, management, and future perspectives[J]. Semin Thromb Hemost, 2026. DOI: 10.1055/a-2848-9427.[ Epub ahead of print]
[38]	Lê G N, Dillon A, Smith O P, et al. Thrombocytosis and the generation of platelet-derived microparticles in the pathophysiology of sickle cell disease[J]. Br J Haematol, 2026, 209( 2): 420- 431. DOI: 10.1111/bjh.70579.
[39]	Balaphas A, Meyer J, Sadoul K, et al. Platelets and platelet-derived extracellular vesicles in liver physiology and disease[J]. Hepatol Commun, 2019, 3( 7): 855- 866. DOI: 10.1002/hep4.1358.
[40]	Li H Y, Xu Y, Chen Y F, et al. Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: A phase 1/2 trial[J]. Nat Med, 2026, 32( 6): 2026- 2036. DOI: 10.1038/s41591-026-04366-x.
[41]	Palviainen M, Puutio J, Østergaard R H, et al. Beyond basic characterization and omics: Immunomodulatory roles of platelet-derived extracellular vesicles unveiled by functional testing[J]. J Extracell Vesicles, 2024, 13( 10): e12513. DOI: 10.1002/jev2.12513.
[42]	Shi W X, Yan H W, Liu X L, et al. Development and validation of a novel prognostic nomogram based on platelet and CD8⁺T cell counts in hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. J Hepatocell Carcinoma, 2024, 11: 1049- 1063. DOI: 10.2147/JHC.S452688.
[43]	Yan H W, Zhou D D, Liu X L, et al. Survival analysis of patients with hepatocellular carcinoma based on the ratio of platelet count to spleen diameter[J]. Front Pharmacol, 2024, 15: 1449603. DOI: 10.3389/fphar.2024.1449603.
[44]	Task Force on“Expert opinion on perioperative management of bleeding and coagulation in anesthesiology(2026 edition)”. Expert opinion on perioperative management of bleeding and coagulation in anesthesiology(2026 edition)[J]. Chin J Anesthesiol, 2026, 46( 1): 79- 93. DOI: 10.3760/cma.j.cn131073-20251028-00108. 《围手术期出凝血管理麻醉专家意见(2026版)》工作组. 围手术期出凝血管理麻醉专家意见(2026版)[J]. 中华麻醉学杂志, 2026, 46( 1): 79- 93. DOI: 10.3760/cma.j.cn131073-20251028-00108.
[45]	Casselman F P A, Lance M D, Ahmed A, et al. 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP[J]. Eur J Cardiothorac Surg, 2025, 67( 5): ezae352. DOI: 10.1093/ejcts/ezae352.
[46]	Huang A, Chen J F, Wu J Z, et al. Effectiveness and safety of avatrombopag in liver cancer patients with severe thrombocytopenia: Real-world data and challenges[J]. J Oncol, 2022, 2022( 1): 9138195. DOI: 10.1155/2022/9138195.
[47]	Ding Z B, Wu H, Zeng Y Y, et al. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures[J]. Hepatol Int, 2023, 17( 1): 180- 189. DOI: 10.1007/s12072-022-10421-9.
[48]	Wu R H, Gao J, Liu Y F, et al. Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial[J]. Blood, 2025, 146: 4804. DOI: 10.1182/blood-2025-4804.
[49]	National Medical Center for Infectious Diseases; Society of Infectious Diseases, Chinese Medical Association; Editorial Committee of Chinese Journal of Infectious Diseases. Guidelines on the prevention and treatment of hepatitis B virus reactivation in high-risk populations in China(Version 2026)[J]. J Clin Hepatol, 2026, 42( 7): 1541- 1550. DOI: 10.12449/JCH260709. 国家传染病医学中心, 中华医学会感染病学分会,《中华传染病杂志》编辑委员会. 中国高危人群乙型肝炎病毒再激活防治指南(2026年版)[J]. 临床肝胆病杂志, 2026, 42( 7): 1541- 1550. DOI: 10.12449/JCH260709.
[50]	Chen Y F, Liu J Y, Dai J W, et al. Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: A multicentre, prospective, open-label, randomised controlled trial[J]. Ann Hematol, 2026, 105( 4): 140. DOI: 10.1007/s00277-026-06908-2.
[51]	Stolz S M, Schwotzer R, Rösler W, et al. Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia-a single centre retrospective analysis[J]. Br J Haematol, 2024, 205( 3): 1121- 1125. DOI: 10.1111/bjh.19629.
[52]	Pincez T, Fernandes H, Leverger G, et al. Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: A propensity score-matched study[J]. Blood Adv, 2026, 10( 3): 563- 574. DOI: 10.1182/bloodadvances.2025017536.
[53]	Wu Y Y, Li H Y, Zhang T S, et al. Splanchnic vein thrombosis in liver cirrhosis after splenectomy or splenic artery embolization: A systematic review and meta-analysis[J]. Adv Ther, 2021, 38( 4): 1904- 1930. DOI: 10.1007/s12325-021-01652-7.
[54]	Gamme G, Birch D W, Karmali S. Minimally invasive splenectomy: An update and review[J]. Can J Surg, 2013, 56( 4): 280- 285. DOI: 10.1503/cjs.014312.
[55]	Hematology Branch of China Association of Chinese Medicine, Oncology Committee of Chinese Association of Integrative Medicine, Oncology Committee of Beijing Association of Integrative Medicine, et al. Expert consensus on prevention and treatment of tumor chemotherapy-related thrombocytopenia with traditional Chinese medicine[J]. Beijing J Tradit Chin Med, 2021( 5): 451- 455. DOI: 10.16025/j.1674-1307.2021.05.002. 中华中医药学会血液病分会, 中国中西医结合学会肿瘤专业委员会, 北京中西医结合学会肿瘤专业委员会, 等. 肿瘤化疗相关性血小板减少症中医药防治专家共识[J]. 北京中医药, 2021( 5): 451- 455. DOI: 10.16025/j.1674-1307.2021.05.002.
[56]	Shi Wanxin, Yan Huiwen, Yu Lihua, et al. Treatment of hepatocellular carcinoma-associated thrombocytopenia with the method of benefiting Qi nourishing Yin and detoxifying toxins[J]. Chin J Integr Tradit West Med Liver Dis, 2025, 35( 2): 226- 229. DOI: 10.3969/j.issn.1005-0264.2025.002.019. 石宛鑫, 闫慧文, 于莉华, 等. 从益气养阴解毒法论治肝癌相关血小板减少症[J]. 中西医结合肝病杂志, 2025, 35( 2): 226- 229. DOI: 10.3969/j.issn.1005-0264.2025.002.019.
[57]	Zhu Wenwei, Chen Xinyi, Zhou Yongming. Traditional Chinese medicine expert consensus on the diagnosis and management of adult primary immune thrombocytopenia[J]. China J Tradit Chin Med Pharm, 2022, 37( 4): 2129- 2133. 朱文伟, 陈信义, 周永明. 成人原发免疫性血小板减少症中医诊治专家共识[J]. 中华中医药杂志, 2022, 37( 4): 2129- 2133.
[58]	Yu Hong, Wang Weitao, Ji Jun’an, et al. Observation on the therapeutic effect of Qijiaoshengbai capsule combined with granulocyte colony stimulating factor on bone marrow suppression after cancer chemotherapy[J]. Mod J Integr Tradit Chin West Med, 2019, 28( 6): 621- 623. 于红, 王维涛, 嵇钧安, 等. 芪胶升白胶囊联合粒细胞集落刺激因子治疗癌症化疗后骨髓抑制疗效观察[J]. 现代中西医结合杂志, 2019, 28( 6): 621- 623.
[59]	Ye Peizhi, Cui Xiaohong, Zhang Yurong, et al. Research progress on traditional Chinese medicine for prevention and treatment of chemotherapy-induced thrombocytopenia in tumors[J]. China Mod Med, 2025, 32( 22): 189- 194. DOI: 10.3969/j.issn.1674-4721.2025.22.40. 叶霈智, 崔晓红, 张育荣, 等. 中医药防治肿瘤化疗相关血小板减少症的研究进展[J]. 中国当代医药, 2025, 32( 22): 189- 194. DOI: 10.3969/j.issn.1674-4721.2025.22.40.
[60]	Song Jing, Cheng Ling, Wang Xiaopu, et al. Whole course management and therapeutic strategy of traditional Chinese medicine for thrombocytopenia induced by tumor treatment[J]. J Tradit Chin Med, 2023, 64( 21): 2184- 2187. DOI: 10.13288/j.11-2166/r.2023.21.005. 宋璟, 程玲, 王小璞, 等. 肿瘤治疗所致血小板减少症的中医药全程管理及诊疗策略[J]. 中医杂志, 2023, 64( 21): 2184- 2187. DOI: 10.13288/j.11-2166/r.2023.21.005.
[61]	Li J, Cai D C, Yao X, et al. Protective effect of ginsenoside Rg1 on hematopoietic stem/progenitor cells through attenuating oxidative stress and the Wnt/β-catenin signaling pathway in a mouse model of d-galactose-induced aging[J]. Int J Mol Sci, 2016, 17( 6): 849. DOI: 10.3390/ijms17060849.
[62]	Bao W R, Zhang Q W, Zheng H M, et al. Radix astragali polysaccharide RAP directly protects hematopoietic stem cells from chemotherapy-induced myelosuppression by increasing FOS expression[J]. Int J Biol Macromol, 2021, 183: 1715- 1722. DOI: 10.1016/j.ijbiomac.2021.05.120.
[63]	Lee J G, Hsieh W T, Chen S U, et al. Hematopoietic and myeloprotective activities of an acidic Angelica sinensis polysaccharide on human CD34⁺ stem cells[J]. J Ethnopharmacol, 2012, 139( 3): 739- 745. DOI: 10.1016/j.jep.2011.11.049.
[64]	Sun C J, Su S L, Zhu Y, et al. Salvia miltiorrhiza stem-leaf active components of salvianolic acids and flavonoids improved the hemorheological disorder and vascular endothelial function on microcirculation dysfunction rats[J]. Phytother Res, 2020, 34( 7): 1704- 1720. DOI: 10.1002/ptr.6652.
[65]	Gao Q Y, Li G D, Zu Y, et al. Ginsenoside Rg1 alleviates ANIT-induced cholestatic liver injury by inhibiting hepatic inflammation and oxidative stress via SIRT1 activation[J]. J Ethnopharmacol, 2024, 319( Pt 1): 117089. DOI: 10.1016/j.jep.2023.117089.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (121) PDF downloads(64)

Precise management of hepatopathy-related thrombocytopenia

DOI: 10.12449/JCH260902

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Precise management of hepatopathy-related thrombocytopenia

DOI: 10.12449/JCH260902

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content